Reference for Chapter 21: Principles of Phototherapy

1 Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop report. Br J Dermatol 2004;151:283–297. Cross Ref link Pubmed link
2 Berneburg M, Rocken M, Benedix F. Phototherapy with narrowband UVB. Acta Derm Venereol 2005;85:1–11. Cross Ref link
3 Gupta AK, Anderson TF. Psoralen photochemotherapy. J Am Acad Dermatol 1987;17:703–34. Cross Ref link Pubmed link
4 Honigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001;26:343–50. Cross Ref link Pubmed link
5 Edelson RL, Berger C, Gasparro F, et al. Treatment of cutaneous T‐cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987:316:297–303. Cross Ref link Pubmed link
6 McKenna KE, Whittaker S, Rhodes LE, et al. Evidence based practice of photopheresis 1987–2001: a report of a workshop of the British Photodermatology Group and UK Skin Lymphoma Group. Br J Dermatol 2006;154:7–20. Cross Ref link Pubmed link
7 Krutmann J, Czech W, Diepgen T, et al. High‐dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992;26:225–30. Cross Ref link Pubmed link
8 Kerscher M, Volkenandt M, Gruss C, et al. Low‐dose UVA1 phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998;38:21–6. Cross Ref link Pubmed link
9 El‐Ghorr AA, Norval M. Biological effects of narrow‐band (311 nm TL01) UVB irradiation: a review. J Photochem Photobiol B Biol 1997;38:99–106. Cross Ref link
10 Ozawa M, Ferenczi K, Kikuchi T, et al. 312‐nanometer ultraviolet B light (narrow‐band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999;189:711–18. Cross Ref link Pubmed link
11 Aufiero BM, Talwar H, Young C, et al. Narrow band UVB induces apoptosis in human keratinocytes. J Photochem Photobiol 2006;82:132–9. Cross Ref link
12 Pathak MA. Mechanisms of psoralen photosensitization reactions. Natl Cancer Inst Monogr 1984;66:41–6. Pubmed link
13 Okamoto H, Takigawa M, Horio T. Alteration of lymphocyte functions by 8‐methoxypsoralen and long‐wave ultraviolet radiation. I. Suppressive effects of PUVA on T‐lymphocyte migration in vitro. J Invest Dermatol 1985;84:203–5. Cross Ref link Pubmed link
14 Furuhashi T, Saito C, Torii K, et al. Photo(chemo)therapy reduces circulatory Th17 cells and restores circulating regulatory T cells in psoriasis. PLOS One 2013;8:e54895. Pubmed link
15 Berger CL, Xu A‐L, Hanlon D. Induction of tumor loaded dendritic cells. Int J Cancer 2001;91:438–77. Cross Ref link Pubmed link
16 Di Renzo M, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T cell lymphoma. Immunology 1997;92:99–103. Cross Ref link Pubmed link
17 Vowels BR, Cassin M, Boufal MH, et al. Extracorporeal photochemotherapy induces the production of tumor necrosis factor‐alpha in monocytes: implications for the treatment of cutaneous T‐cell lymphoma and systemic sclerosis. J Invest Dermatol 1992;98:686–92. Cross Ref link Pubmed link
18 Gruss C, Reed JA, Altmeyer P, et al. Induction of interstitial collagenase (MMP‐1) by UVA‐1 phototherapy in morphea fibroblasts. Lancet 1997;350:1295–6. Cross Ref link Pubmed link
19 Gambichler T, Kreuter A, Tomi NS, et al. Gene expression of cytokines in atopic eczema before and after ultraviolet A1 phototherapy. Br J Dermatol 2008;158:1117–20. Cross Ref link Pubmed link
20 Godar DE. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 1999;112:3–12. Cross Ref link Pubmed link
21 Roelandts R. The history of phototherapy: something new under the sun? J Am Acad Dermatol 2002;46:926–30. Cross Ref link Pubmed link
22 Honigsmann H. History of phototherapy in dermatology. J Photochem Photobiol Sci 2013;12:16–21. Cross Ref link
23 Roelandts R. Bicentenary of the discovery of the ultraviolet rays. Photoderm Photoimmunol Photomed 2002;18:208. Cross Ref link
24 Downes AH, Blunt TP. Researches on the effect of light upon bacteria and other organisms. Proc R Soc London 1877;26:488–500. Cross Ref link
25 Moller KI, Kongshoi B, Philipsen PA, Thomsen VO, Wulf HC. How Finsen's light cured lupus vulgaris. Photodermatol Photoimmunol Photomed 2005;21:118–24. Cross Ref link Pubmed link
26 Alderson HE. Heliotherapy in psoriasis. Arch Dermatol 1923;8:79–80. Cross Ref link
27 Goeckerman WH. The treatment of psoriasis. Northwest Med 1925;24:229–31.
28 Ingram JT. The approach to psoriasis. BMJ 1953;12:591–4. Cross Ref link
29 Parrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1981;76:359–62. Cross Ref link Pubmed link
30 Van Weelden H, Baart de La Faille H, Young E, van der Leun JC. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988;119:11–19. Cross Ref link Pubmed link
31 Green C, Ferguson J, Lakshmipathi T, Johnson BE. 311 nm UVB phototherapy – an effective treatment for psoriasis. Br J Dermatol 1988;119:691–6. Cross Ref link Pubmed link
32 Fahmy IR, Abu‐Shady H, Schonberg AA. Crystalline principle from Ammi majus. Nature 1947;160:468. Cross Ref link Pubmed link
33 Fahmy IR, Abu‐Shady H. Ammi majus Linn: the isolation and properties of ammoidin, ammidin and majudin, and their effect in the treatment of leukoderma. Q J Pharm Pharmacol 1948;21:499–503. Pubmed link
34 El‐Mofty AM. A preliminary clinical report on the treatment of leukoderma with Ammi majus Linn. J Egypt Med Assoc 1948;31:651–65. Pubmed link
35 Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974;291:1207–11. Cross Ref link Pubmed link
36 Mutzhas MF, Hofmann C, Plewig G. A new apparatus with high radiation energy between 320–460 nm – physical description and dermatological applications. J Invest Dermatol 1981;76:42–47. Cross Ref link Pubmed link
37 Taylor DK, Anstey AV, Coleman AJ, et al. Guidelines for dosimetry and calibration in ultraviolet radiation therapy: a report of a British Photodermatology Group workshop. Br J Dermatol 2002;146:755–63. Cross Ref link Pubmed link
38 Young AR. Cumulative effects of ultraviolet radiation on the skin: cancer and photoaging. Semin Dermatol 1990;9:25–31. Pubmed link
39 Diffey BL, Hart GC. Ultraviolet and Blue‐light Phototherapy – Principles, Sources, Dosimetry and Safety. Report No. 76. York: Institute of Physics and Engineering in Medicine, 1997:27.
40 Kerr AC, Ferguson J, Attili SK, et al. Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. Clin Exp Dermatol 2012;37 (3):219–26. Cross Ref link Pubmed link
41 Dawe RS. A quantitative review of studies comparing the efficacy of narrow‐band and broad‐band ultraviolet B for psoriasis. Br J Dermatol 2003;149:669–72. Cross Ref link Pubmed link
42 Markham T, Rogers S, Collins P. Narrowband UV‐B (TL‐01) phototherapy vs oral 8‐methoxypsoralen psoralen‐UV‐A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003;139:325–8. Cross Ref link Pubmed link
43 Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double‐blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen‐UV‐A therapy vs narrowband UV‐B therapy. Arch Dermatol 2006;142:836–42. Cross Ref link Pubmed link
44 Robinson A, Van Voohees AS, Hsu S, et al. Treatment of pustular psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2012;67:279–88. Cross Ref link Pubmed link
45 Jekler J, Larko O. UVA solarium versus UVB phototherapy of atopic dermatitis: a paired comparison study. Br J Dermatol 1991;125:569–72. Cross Ref link Pubmed link
46 Midelfart K, Stenvold S‐E, Volden G. Combined UVB and UVA phototherapy of atopic eczema. Dermatologica 1985;171:95–8. Cross Ref link Pubmed link
47 Hudson‐Peacock MJ, Diffey BL, Farr PM. Narrowband UV‐B phototherapy for severe atopic dermatitis. Br J Dermatol 1995;133:653–67. Cross Ref link Pubmed link
48 Sheehan MP, Atherton DJ, Norris P, Hawk JLM. Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. Br J Dermatol 1993;129:431–7. Cross Ref link Pubmed link
49 British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Br J Dermatol 1993;130:246–55.
50 Gathers RC, Scherschun L, Malick F, Fivenson DP, Lim HW. Narrowband UVB phototherapy for early‐stage mycosis fungoides. J Am Acad Dermatol 2002;47:191–7. Cross Ref link Pubmed link
51 Honigsmann H, Tanew A, Wolff K. Treatment of mycosis fungoides with PUVA. Photodermatol 1987;4:55–8. Pubmed link
52 Herrmann JJ, Roenigk HH, Jr, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long‐term follow‐up. J Am Acad Dermatol 1995;33:234–42. Cross Ref link Pubmed link
53 Tjioe M, Gerritsen MJ, Juhlin L, van de Kerkhof PC. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol 2002;82:369–72. Cross Ref link Pubmed link
54 Grimes PE, Minus HR, Chakrabarti SG, et al. Determination of optimal photochemotherapy for vitiligo. J Am Acad Dermatol 1982;7:771–8. Cross Ref link Pubmed link
55 Pacificio A, Leone G. Photo(chemo)therapy for vitiligo. Photodermatol Photoimmunol Photomed 2011;27:261–77. Cross Ref link Pubmed link
56 Bilsland D, George SA, Gibbs NK, Aitchison T, Johnson BE, Ferguson J. A comparison of narrow band phototherapy (TL‐01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol 1993;129:708–12. Cross Ref link Pubmed link
57 Dummer R, Ivanova K, Scheidegger EP, Burg G. Clinical and therapeutic aspects of polymorphous light eruption. Dermatology 2003;207:93–5. Cross Ref link Pubmed link
58 Van der Schaar WW, Sillevis Smitt JH. Evaluation of PUVA‐therapy for alopecia areata. Dermatologica 1984;168:250–2. Cross Ref link Pubmed link
59 Assouly P. Alopecia areata: update on therapy. Ann Dermatol Venereol 2002;129:831–6. Pubmed link
60 Grundmann‐Kollmann M, Martin H, Ludwig R, et al. Narrowband UV‐B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation 2002;74:1631–4. Cross Ref link Pubmed link
61 Jampel RM, Farmer ER, Vogelsang BB, et al. PUVA therapy for chronic cutaneous graft‐vs‐host disease. Arch Dermatol 1991;127:1673–8. Cross Ref link Pubmed link
62 Browne F, Turner D, Goulden V. Psoralen and ultraviolet A in the treatment of granuloma annulare. Photoderm Photoimmunol Photomed 2011;27:81–4. Cross Ref link
63 Saricaoglu H, Karadogan SK, Baskan EB, Tunali S. Narrowband UVB therapy in the treatment of lichen planus. Photodermatol Photoimmunol Photomed 2003;19:265–7. Cross Ref link Pubmed link
64 Wackernagel A, Legat FJ, Hofer A, et al. Psoralen plus UVA vs UVB‐311nm for the treatment of lichen planus. Photoderm Photoimmunol Photomed 2007;23:15–19. Cross Ref link
65 McKenna DB, Cooper EJ, Tidman MJ. Topical psoralen plus ultraviolet A treatment for necrobiosis lipoidica. Br J Dermatol 2000;143:1333–4. Cross Ref link Pubmed link
66 Tan E, Lim D, Rademaker M. Narrowband UVB phototherapy in children. A New Zealand experience. Australas J Dermatol 2010;51:268–73. Cross Ref link Pubmed link
67 Streit V, Thiede R, Wiedow O, Christophers E. Foil bath PUVA in the treatment of prurigo simplex subacuta. Acta Derm Venereol (Stockh) 1987;82:317–20.
68 Collins P, Ferguson J. Narrow‐band UVB (TL‐01) UVB phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995;132:956–63. Cross Ref link Pubmed link
69 Roelandts R. Phototherapy of photodermatoses. J Dermatol Treat 2002;13(4):157–60. Cross Ref link
70 Honigsmann H. Mechanisms of phototherapy and photochemotherapy for photodermatoses. Dermatol Ther 2003;16:23–7. Cross Ref link Pubmed link
71 Rosen K, Mobacken H, Swanback G. PUVA, etretinate, and PUVA‐etretinate therapy for pustulosis palmoplantaris. Arch Dermatol 1987;123:885–9. Cross Ref link Pubmed link
72 Farnaghi F, Seirafi H, Ehsani AH, Aghari ME, Noormohammadpour P. Comparison of the therapeutic effects of narrowband UVB vs PUVA in patients with pityriasis lichenoides. J Eur Acad Dermatol Venereol 2011;25:913–16. Cross Ref link Pubmed link
73 Chuh A. Narrow band UVB therapy and oral acyclovir for piyriasis rosea. Photoderm Photoimmunol Photomed 2004;20:64–5. Cross Ref link
74 Vergilis‐Kalner IJ, Mann DJ, Petronic‐Rosic V, Tsoukas MM. Pityriasis rubra pilaris sensitive to narrow band ultraviolet light. J Drugs Dermatol 2009;8:270–3. Pubmed link
75 Kaskel P, Grundmann‐Kollmann M, Schiller PI, et al. Bath‐PUVA is a treatment for pityriasis rubra pilaris provoked by ultraviolet B. Br J Dermatol 1999;140:709–70.
76 Rosen K, Mobacken H, Swanbeck G. Chronic eczematous dermatitis of the hands. A comparison of PUVA and UVB treatment. Acta Derm Venereol 1987;67(1):48–54. Pubmed link
77 Schempp CM, Muller H, Czech W, et al. Treatment of chronic palmoplantar eczema with local bath‐PUVA therapy. J Am Acad Dermatol 1997;36:733–7. Cross Ref link Pubmed link
78 Hsu MM, Yang CC. Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. Br J Dermatol 2003;149:888–9. Cross Ref link Pubmed link
79 Baldo A, Sammarco E, Plaitano R, et al. Narrowband (TL01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002;147:979–81. Cross Ref link Pubmed link
80 Pirkhammer D, Seeber A, Honigsmann H, Tanew A. Narrow‐band ultraviolet B (ATL‐01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000;143:964–8. Cross Ref link Pubmed link
81 Cameron H, Dawe RS. Subcorneal pustular dermatosis (Sneddon‐Wilkinson disease) treated with narrowband (TL01) UVB phototherapy. Br J Dermatol 1997;137:150–1. Cross Ref link Pubmed link
82 Bauwens M, de Coinck A, Roseeuw D. Subcorneal pustular dermatosis treated with PUVA. Dermatology 1999;198:203–5. Cross Ref link Pubmed link
83 Ridge CA, Moktar A, Barry J, Murphy GM. Photochemotherapy and methotrexate used to treat generalised cutaneous scleroderma. J Eur Acad Dermatol Venereol 2007;21:692–3. Pubmed link
84 Aydogan K, Karadogan SK, Tunali S, Saricaoglu H. Narrowband ultraviolet B (311nm, TL01) phototherapy in chronic ordinary urticaria. Int J Dermatol 2012;51(1):98–103. Cross Ref link Pubmed link
85 Vella Briffa D, Eady RAJ, James MP, et al. Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. Br J Dermatol 1983;109:67–75. Cross Ref link Pubmed link
86 Dawe RS. Ultraviolet A1 phototherapy. Br J Dermatol 2003;148:626–37. Cross Ref link Pubmed link
87 Tzaneva S, Seeber A, Schwaiger M, et al. High‐dose versus medium‐dose UVA1 phototherapy for patients with severe generalised atopic dermatitis. J Am Acad Dermatol 2001;45:503–7. Cross Ref link Pubmed link
88 Kowalzick L. UVA1 For atopic dermatitis: medium dose superior to low dose. J Am Acad Dermatol 2001;44:548. Cross Ref link Pubmed link
89 Morita A, Kobayashi K, Isomura I, et al. Ultraviolet A1 (340–400nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000;43:670–4. Cross Ref link Pubmed link
90 Grundmann‐Kollman M, Behrens S, Gruss C, et al. Chronic sclerodermic graft‐versus‐host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000;42:134–6. Cross Ref link Pubmed link
91 Tran KT, Prather HB, Cockerell CJ, Jacobe H. UV‐A1 therapy for nephrogenic systemic fibrosis. Arch Dermatol 2009;145:1170–4. Cross Ref link Pubmed link
92 Kreuter A, Gambichler T, Avermaete A, et al. Low‐dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol 2002;46:251–5. Cross Ref link Pubmed link
93 Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. UVA1 phototherapy for genital lichen sclerosus. Clin Exp Dermatol 2000;31:343–7. Cross Ref link
94 McGrath H, Jr. Ultraviolet‐A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:129–35. Pubmed link
95 Polderman MC, Huizinga TW, Le Cessie S, Pavel S. UVA‐1 cold light treatment of SLE: a double blind, placebo controlled crossover trial. Ann Rheum Dis 2001;60:112–15. Cross Ref link Pubmed link
96 Scarisbrick JJ, Taylor P, Holtick U, et al. UK consensus statement on the use of extracorporeal photopheresis for the treatment of cutaneous T‐cell lymphoma and chronic graft‐versus‐host disease. Br J Dermatol 2008;158:1365–2133. Cross Ref link
97 Kim YH, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 1995;131:1003–8. Cross Ref link Pubmed link
98 Fraser‐Andrew E, Seed P, Whittaker S, Rusell‐Jones R. Extracorporeal photopheresis in Sezary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T‐cell clone. Arch Dermatol 1998;134:1001–5. Pubmed link
99 Child FJ, Ratnavel R, Watkins P et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft‐versus‐host disease (GVHD). Bone Marrow Transplant 1999;23:881–7. Cross Ref link Pubmed link
100 Rossetti D, Dall'Amico R, Crovetti G, et al. Extracorporeal photochemotherapy for the treatment of graft‐versus‐host disease. Bone Marrow Transplant 1996;18:175–81. Pubmed link
101 Greinix HT, Volc‐Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft‐versus‐host disease. Blood 1998;92:3098–104. Pubmed link
102 Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Arch Dermatol 1992;128:337–46. Cross Ref link Pubmed link
103 Wollina U, Lange D, Looks A. Short‐time extracorporeal photochemotherapy in the treatment of drug‐resistant autoimmune bullous diseases. Dermatology 1999;198:140–4. Cross Ref link Pubmed link
104 Vonderheid EC, Bigler RD, Rogers TJ, Kadin ME, Griffin TD. Effect of extracorporeal photopheresis on selected immunologic parameters in psoriasis vulgaris. Yale J Biol Med 1989;62:653–64. Pubmed link
105 Prinz B, Nachbar F, Plewig G. Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch Dermatol Res 1994;287:48–52. Cross Ref link Pubmed link
106 Bécherel PA, Bussel A, Chosidow O, Rabian C, Piette JC, Francès C. Extracorporeal photochemotherapy for chronic erosive lichen planus. Lancet 1998;351:805.
107 Knobler RM, Graninger W, Graninger W, Lindmaier A, Trautinger F, Smolen JS. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. Arthritis Rheum 1992;35:319–24. Cross Ref link Pubmed link
108 Stables GI, Taylor PC, Highet AS. Scleredema associated with paraproteinaemia treated by extracorporeal photopheresis. Br J Dermatol 2000;142:781–3. Cross Ref link Pubmed link
109 De Wilde A, DiSpaltro FX, Geller A, Szer R, Klainer AS, Bisaccia E. Extracorporeal photochemotherapy as adjunctive treatment in juvenile dermatomyositis: a case report. Arch Dermatol 1992;128:1656–7. Cross Ref link Pubmed link
110 Barr Ml, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998;339:1744–51. Cross Ref link Pubmed link
111 Heald PW, Perez MI, Christensen I, et al. Photopheresis therapy of cutaneous T‐cell lymphoma: the Yale–New Haven Hospital experience. Yale Biol Med 1989;62:629–38.
112 Wolf JT, Lessin SR, Singh AH, Rook AH. Review of immunomodulation by photopheresis: treatment of cutaneous T‐cell lymphoma, autoimmune disease, and allograft rejection. Artif Organs 1994;18:888–97. Cross Ref link Pubmed link
113 Gottleib SL, Wolfe JT, Foc FE, et al. Treatment of cutaneous T‐cell lymphoma with extracorporeal photophoresis monotherapy and in combination with recombinant interferon‐alpha: a 10 year experience at a single institution. J Am Acad Dermatol 1996;35:946–57. Cross Ref link Pubmed link
114 Evans AV, Wood BP, Scarisbrick JJ, et al. Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response. Blood 2001;98:1298–301. Cross Ref link Pubmed link
115 Heald PW, Rook A, Perez MI, et al. Treatment of erythrodermic cutaneous T‐cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992;27:427–33. Cross Ref link Pubmed link
116 Armus S, Keyes B, Cahill C, et al. Photopheresis for the treatment of cutaneous T‐cell lymphoma. J Am Acad Dermatol 1990;23:898–902. Cross Ref link Pubmed link
117 Rubegni P, De Aloe G, Fimiani M. Extracorporeal photochemotherapy in long‐term treatment of early stage cutaneous T‐cell lymphoma. Br J Dermatol 2000;143:894–6. Cross Ref link Pubmed link
118 Fimiani M, Rubegni P, D'Ascenzo G, Andreassi L. Extracorporeal photochemotherapy in the early treatment of cutaneous T‐cell lymphoma. J Am Acad Dermatol 1994;31:828–9. Cross Ref link Pubmed link
119 Dippel E, Schrag ED, Goerdt S, Orfanos CE. Extracorporeal photopheresis and interferon‐α in advanced cutaneous T‐cell lymphoma. Lancet 1997;350:32–3. Cross Ref link Pubmed link
120 Tsirigotis P, Pappa V, Papageorgiou S, et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and sezary syndrome. Br J Dermatol 2007;156(6):1379–81. Cross Ref link Pubmed link
121 Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000;43:54–60. Cross Ref link Pubmed link
122 Studniberg HM, Weller P. PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol 1993;29:1013–22. Cross Ref link Pubmed link
123 Morison WL, Baughman RD, Day RM, et al. Consensus workshop on the toxic effects of long‐term PUVA therapy. Arch Dermatol 1998;134:595–8. Pubmed link
124 Farr PM, Diffey BL. Quantitative studies on cutaneous erythema induced by ultraviolet radiation. Br J Dermatol 1984;111:673–82. Cross Ref link Pubmed link
125 Gordon PM, Saunders PJ, Diffey BL, Farr PM. Phototesting prior to narrowband (TL‐01) UV‐B phototherapy. Br J Dermatol 1998;139:811–14. Cross Ref link Pubmed link
126 Farr PM. Irradiation testing of the skin. In: Hawk JLM, ed. Photodermatology. London: Arnold, 1999:261–5.
127 Otman SG, Edwards C, Gambles B, Anstey AV. Validation of a semiautomated method of minimal erythema dose testing for narrowband ultraviolet B phototherapy. Br J Dermatol 2006;155(2):416–21. Cross Ref link Pubmed link
128 Dawe RS, Cameron HM, Yule S, et al. A randomized comparison of methods of selecting narrowband UV‐B starting dose to treat chronic psoriasis. Arch Dermatol 2011;147(2):168–74. Cross Ref link Pubmed link
129 Wainwright NJ, Dawe RS, Ferguson J. Narrowband ultraviolet B (TL‐01) phototherapy for psoriasis: which incremental regimen? Br J Dermatol 1998;139:410–14. Cross Ref link Pubmed link
130 Dawe RS, Wainwright NJ, Cameron H, Ferguson J. Narrow‐band (TL‐01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 1998;138:833–9. Cross Ref link Pubmed link
131 Asawanonda P, Chingchai A, Torranin P. Targeted UV‐B phototherapy for plaque‐type psoriasis. Arch Dermatol 2005;141:1542–6. Cross Ref link Pubmed link
132 Mudigonda T, Dabade TS, Feldman SR. A review of targeted ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol 2012;66(4):664–72. Cross Ref link Pubmed link
133 Trehan M, Taylor C. High‐dose 308‐nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 2002;46:732–7. Cross Ref link Pubmed link
134 Jordan WP, Jr, Clarke AM, Hale RK. Long‐term modified Goekerman regimen for psoriasis using an ultraviolet B light source in the home. J Am Acad Dermatol 1981;4:584–91. Cross Ref link Pubmed link
135 Cameron H, Yule S, Moseley H, Dawe RS, Ferguson J. Taking treatment to the patient: development of a home ultraviolet B phototherapy service. Br J Dermatol 2002;147:957–65. Cross Ref link Pubmed link
136 Sarkany RPE, Anstey A, Diffey BL, et al. Home phototherapy: report on a workshop of the British Photodermatology Group, December 1996. Br J Dermatol 1999;140:195–9. Cross Ref link Pubmed link
137 Koek MBG, Buskens E, van Weeelden H, et al. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomized controlled non‐inferiority trial (PLUTO study). BMJ 2009;338:1181–6. Cross Ref link
138 Anstey A. Home UVB phototherapy for psoriasis: is as safe and effective as outpatient treatment, but provision is poor. BMJ 2009;338:1153–4. Cross Ref link
139 Stern RS. Psoralen and ultraviolet light therapy for psoriasis. N Engl J Med 2007;357:682–90. Cross Ref link Pubmed link
140 Sakuntabhai A, Diffey BL, Farr PM. Calculation of 8‐methoxypsoralen dose according to body surface area in PUVA treatment. Br J Dermatol 1995;133:919–23. Cross Ref link Pubmed link
141 Halpern SM, Anstey AV, Dawe RS, et al. Guidelines for topical PUVA: a report of a Workshop of the British Photodermatology Group. Br J Dermatol 2000;142:22–31. Cross Ref link Pubmed link
142 Koulu LM, Jansen CT. Skin photosensitizing and Langerhans' cell depleting activity of topical (bath) PUVA therapy: comparison of trimethylpsoralen and 8‐methoxypsoralen. Acta Derm Venereol (Stockh) 1983;63:137–41.
143 Konya J, Diffey BL, Hindson TC. Time course of activity of topical 8‐methoxypsoralen on palmoplantar skin. Br J Dermatol 1992;127:654–5. Cross Ref link Pubmed link
144 Ibbotson SH, Farr PM. The time‐course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol 1999;113:346–50. Cross Ref link Pubmed link
145 Buckley DA, Healy E, Rogers S. A comparison of twice‐weekly MPD‐PUVA and three times‐weekly skin typing‐PUVA regimens for the treatment of psoriasis. Br J Dermatol 1995;133:417–22. Cross Ref link Pubmed link
146 Collins P, Wainwright NJ, Amorim I, et al. 8‐MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose‐based regimen with a skin‐type approach. Br J Dermatol 1996;135:248–54. Cross Ref link Pubmed link
147 Sakuntabhai A, Sharpe GR, Farr PM. Response of psoriasis to twice weekly PUVA. Br J Dermatol 1993;128:166–71. Cross Ref link Pubmed link
148 Behrens‐Williams S, Gruss C, Grundmann‐Kollmann M, et al. Assessment of minimal phototoxic dose following 8‐methoxypsoralen bath: maximal reaction on average after 5 days. Br J Dermatol 2000;142:112–15. Cross Ref link Pubmed link
149 Grundmann‐Kollmann M, Leiter U, Behrens S, et al. The time course of phototoxicity of topical PUVA: 8‐methoxypsoralen cream‐PUVA vs. 8‐methoxypsoralen gel‐PUVA. Br J Dermatol 1999;140:988–90. Cross Ref link Pubmed link
150 Berne B, Blom I, Spangberg S. Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base. A single‐blind controlled study. Acta Derm Venereol (Stockh) 1990;70:474–7.
151 Menkes A, Stern RS, Arndt KA. Psoriasis treatment with suberythemogenic ultraviolet B radiation and coal tar extract. J Am Acad Dermatol 1985;12:21–5. Cross Ref link Pubmed link
152 Carrozza P, Hausermann P, Nestle FO, et al. Clinical efficacy of narrow‐band UVB (311nm) combined with dithranol in psoriasis. An open pilot study. Dermatology 2000;200:35–9. Cross Ref link Pubmed link
153 Koo JY. Tazarotene in combination with phototherapy. J Am Acad Dermatol 1998;39(4 Pt 2):S144–8. Cross Ref link Pubmed link
154 Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo‐controlled clinical trial. Br J Dermatol 2003;149:146–50. Cross Ref link Pubmed link
155 Speight EL, Farr PM. Calciotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994;130:79–82. Cross Ref link Pubmed link
156 Lebwohl M, Quijije J, Gilliard J, et al. Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol 2003;121:594–5. Cross Ref link Pubmed link
157 Schiffner R, Schiffner‐Rohe J, Wolf G, et al. Evaluation of a multicentre study of synchronous application of narrowband ultraviolet B phototherapy (TL01) and bathing in Dead Sea salt solution for psoriasis vulgaris. Br J Dermatol 2000;142:740–7. Cross Ref link Pubmed link
158 Green C, Lakshmipathi T, Johnson BE, Ferguson J. A comparison of the efficacy and relapse rates of narrow‐band UVB (TL01) monotherapy vs. etretinate (re‐TL01) vs. etretinate‐PUVA (re‐PUVA) in the treatment of psoriasis patients. Br J Dermatol 1992;127:5–9. Cross Ref link Pubmed link
159 Nijsten TEC, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen‐UVA: a nested cohort study. J Am Acad Dermatol 2003;49:644–50. Cross Ref link Pubmed link
160 Marcil I, Stern RS. Squamous cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort study. Lancet 2001;358:1042–5. Cross Ref link Pubmed link
161 Legat FJ, Hofer A, Wackernagel A, et al. Narrowband UV‐B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007;143:1016–22. Cross Ref link Pubmed link
162 Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol 2011;164:1383–6. Cross Ref link Pubmed link
163 Wolf P, Hofer A, Weger W, et al. 311nm ultraviolet B‐accelerated response of psoriatic lesions in adalimumab‐treated patients. Photodermatol Photoimmunol Photomed 2011;27:186–9. Cross Ref link Pubmed link
164 Wolf P, Weger W, Legat FJ, et al. Treatment of 311‐nm ultraviolet B‐enhanced response of psoriatic lesions in ustekinumab‐treated patients: a randomized intraindividual trial. Br J Dermatol 2012;166:147–53. Cross Ref link Pubmed link
165 Christensen I, Heald P. Photopheresis in the 1990's. J Clin Apheresis 1991;6:216–20. Cross Ref link Pubmed link
166 Heald P, Perez M, Gasparro F. Dosage guidelines: extracorporeal photochemotherapy (photopheresis). Arch Dermatol 1990;126:1369. Cross Ref link Pubmed link
167 Shephard SE, Nestle FO, Panizzon R. Pharmacokinetics of 8‐methoxypsoralen during extracorporeal photopheresis. Photodermatol Photoimmunol Photomed 1999;15:64–74. Cross Ref link Pubmed link
168 Man I, Dawe RS, Ferguson J, Ibbotson SH. An intraindividual study of the characteristics of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. Photochem Photobiol 2003;78:55–60. Cross Ref link Pubmed link
169 Laube S, George SA. Adverse effects with PUVA and UVB. J Dermatol Treat 2001;12:101–5. Cross Ref link
170 Perna JJ, Mannix ML, Rooney JF, et al. Reactivation of latent herpes simplex virus infection by ultraviolet light: a human model. J Am Acad Dermatol 1987;17:473–8. Cross Ref link Pubmed link
171 George SA, Ferguson J. Lesional blistering following narrow‐band (TL‐01) UVB phototherapy for psoriasis: a report of four cases. Br J Dermatol 1992;127:445–6. Cross Ref link Pubmed link
172 Pasker‐de Jong PCM, Wielink G, van der Valk PGM, van der Wilt G‐J. Treatment with UV‐B for psoriasis and non‐melanoma skin cancer. Arch Dermatol 1999;135:834–40. Pubmed link
173 Stern RS and Members of the Photochemotherapy Follow‐up Study. Genital tumours among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. N Engl J Med 1990;322:1093–7. Cross Ref link Pubmed link
174 Young AR. Carcinogenicity of UVB phototherapy assessed. Lancet 1995;345:1431–2. Cross Ref link
175 Weischer M, Blum A, Eberhard F, et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB photherapy: a first retrospective study. Acta Derm Venereol 2004;84:370–4. Cross Ref link Pubmed link
176 Man I, Crombie IK, Dawe RS, et al. The photocarcinogenic risk of narrowband UVB (TL01) phototherapy: early follow‐up data. Br J Dermatol 2005;152:755–7. Cross Ref link Pubmed link
177 Hearn RMR, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow‐band ultraviolet B phototherapy. Br J Dermatol 2008;159:931–5. Cross Ref link Pubmed link
178 Ibbotson SH, Farr PM. The time‐course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol 1999;113:346–50. Cross Ref link Pubmed link
179 Behrens‐Williams S, Gruss C, Grundmann‐Kollmann M, et al. Assessment of minimal phototoxic dose following 8‐methoxypsoralen bath: maximal reaction on average after 5 days. Br J Dermatol 2000;142:112–15. Cross Ref link Pubmed link
180 Morgan JM, Weller R, Adams SJ. Onycholysis in a case of atopic eczema treated with PUVA photochemotherapy. Clin Exp Dermatol 1992;17:65–6. Cross Ref link Pubmed link
181 Wolff K. Side‐effects of psoralen photochemotherapy (PUVA). Br J Dermatol 1990;122:S117–25. Cross Ref link
182 Brickl R, Schmid J, Koss FW. Clinical pharmacology of oral psoralen drugs. Photodermatology 1984;1:174–86. Pubmed link
183 Melski JW, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977;68:328–35. Cross Ref link Pubmed link
184 Tegner E. Severe skin pain after PUVA treatment. Acta Derm Venereol 1979;59:467–70. Pubmed link
185 Van Praag MCG, Tseng LNI, Mommaas AM, et al. Minimising the risks of PUVA treatment. Drug Safety 1993;8:340–9. Cross Ref link Pubmed link
186 Roelandts R, Stevens A. PUVA‐induced itching and skin pain. Photodermatol Photoimmunol Photomed 1990;7:141–2. Pubmed link
187 Burrows NP, Norris PG. Treatment of PUVA‐induced skin pain with capsaicin. Br J Dermatol 1994;131:584–5. Cross Ref link Pubmed link
188 Zamiri M, Bilsland D. Treatment of bath PUVA‐induced skin pain with gabapentin. Br J Dermatol 2004;151:516–17. Cross Ref link Pubmed link
189 Norris PG, Maurice PD, Schott GD,, et al. Persistent skin pain after PUVA. Clin Exp Dermatol 1987;12:403–5. Cross Ref link Pubmed link
190 Kao CL, Krathen RA, Wolf JE, et al. Psoralen plus ultraviolet A‐induced bullous pemphigoid. J Drugs Dermatol 2008;7:695–6. Pubmed link
191 Jeanmougin M, Manciet JR, Castelneau JP, et al. [Systemic photoallergy induced by methoxalen.] Ann Dermatol Venereol 1992;119:277–80. Pubmed link
192 Allen AL, Glaser DA. Disseminated superficial actinic porokeratoses associated with topical PUVA. J Am Acad Dermatol 2000;43:720–2. Cross Ref link Pubmed link
193 Nanda S, Grover C, Reddy BS. PUVA‐induced lichen planus. J Dermatol 2003;30:151–3. Cross Ref link Pubmed link
194 Vernassiere C, Petitpain N, Trechot P, et al. 8‐methoxypsoralen and neurological disorders: from dysosmia to migraine. Photodermatol Photoimmunol Photomed 2006;22:217–18. Cross Ref link Pubmed link
195 Takashima A, Yamamoto K, Kimura S, et al. Allergic contact and photocontact dermatitis due to psoralens in patients with psoriasis treated with topical PUVA. Br J Dermatol 1991;124:37–42. Cross Ref link Pubmed link
196 Park JY, Rim JH, Choe YB, et al. Anaphylaxis to 8‐methoxypsoralen during photochemotherapy. Photodermatol Photoimmunol Photomed 2003;19:37–8. Cross Ref link Pubmed link
197 Matz H. Phototherapy for psoriasis: what to choose and how to use: facts and controversies. Clin Dermatol 2010;28:73–80. Cross Ref link Pubmed link
198 Van Praag MCG, Bouwes Bavinck JN, Bergman W, et al. PUVA keratosis. A clinical and histopathologic entity associated with an increased risk of nonmelanoma skin cancer. J Am Acad Dermatol 1993;28:412–17. Cross Ref link Pubmed link
199 Rhodes AR, Stern RS, Melski JW. The PUVA lentigo: an analysis of predisposing factors. J Invest Dermatol 1983;81:459–63. Cross Ref link Pubmed link
200 Rhodes AR, Harrist TJ, Momtaz TK. The PUVA induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. J Am Acad Dermatol 1983;9:47–58. Cross Ref link Pubmed link
201 Lassacher A, Worda M, Kaddu S, et al. T1799A BRAF mutation is common in PUVA lentigines. J Invest Dermatol 2006;126:1915–18. Cross Ref link Pubmed link
202 Stern RS, Thibodeau LA, Kleinerman RA, et al. Risks of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 1979;300:800–13. Cross Ref link
203 Stern RS, Laird N, Melski J, et al. Cutaneous squamous cell carcinoma in patients treated with PUVA. N Engl J Med 1984;310:1156–61. Cross Ref link Pubmed link
204 Stern RS, Lange R. Non‐melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988;91:120–4. Cross Ref link Pubmed link
205 Stern RS, Lange R. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994;73:2759–64. Cross Ref link Pubmed link
206 Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large‐scale epidemiological study. Lancet 1991;338:91–3. Cross Ref link Pubmed link
207 Lindelof B, Sigurgeirsson B, Tegner E, et al. Comparison of the carcinogenic potential of Trioxsalen bath PUVA and oral methoxsalen PUVA. Arch Dermatol 1992;128:1341–4. Cross Ref link Pubmed link
208 Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow‐up study. Br J Dermatol 1999;141:108–12. Cross Ref link Pubmed link
209 Stern RS; PUVA Follow‐up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30‐year prospective study. J Am Acad Dermatol 2012;66:553–62. Cross Ref link Pubmed link
210 Honigsmann H, Wolff K, Gschnait F, et al. Keratoses and non‐melanoma skin tumours in long‐term photochemotherapy (PUVA). J Am Acad Dermatol 1980;3:406–14. Cross Ref link Pubmed link
211 Tanew A, Honigsmann H, Ortel B, et al. Non‐melanoma skin tumours in long‐term photochemotherapy treatment of psoriasis. J Am Acad Dermatol 1986;15:960–5. Cross Ref link Pubmed link
212 Henseler T, Christophers E, Honigsmann H, et al. Skin tumours in the European PUVA study. J Am Acad Dermatol 1987;16:108–16. Cross Ref link Pubmed link
213 Mali‐gerrits MG, Gaasbeek D, Boezeman J, et al. Psoriasis therapy and the risk of skin cancers. Clin Exp Dermatol 1991;16:85–9. Cross Ref link Pubmed link
214 Fitzsimons CP, Long J, MacKie RM. Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis. Lancet 1983;29:235–6. Cross Ref link
215 Van De Kerkhof PCM, De Rooij MJM. Multiple squamous cell carcinomas in a psoriatic patient following high‐dose photochemotherapy and cyclosporin treatment: response to long‐term acitretin maintenance. Br J Dermatol 1997;136:275–8. Cross Ref link Pubmed link
216 Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non‐melanoma skin cancer in psoralen and ultraviolet A‐treated patients. J Invest Dermatol 2005;124:505–13. Cross Ref link Pubmed link
217 Sage E, Bredberg A. Damage distribution and mutation spectrum: the case of 8‐methoxy‐psoralen and UVA in mammalian cells. Mutat Res 1991;263:217–22. Cross Ref link Pubmed link
218 Peritz AE, Gasparro FP. Psoriasis, PUVA and skin cancer – molecular epidemiology the curious question of T–A transversions. J Invest Dermatol Symp Proc 1999;4:11–16. Cross Ref link
219 Friedmann P. Disappearance of epidermal Langerhans cells during PUVA therapy. Br J Dermatol 1981;105:219–21. Cross Ref link Pubmed link
220 Vella Briffa D, Parker D, Tosca N, et al. The effect of photochemotherapy (PUVA) on cell mediated immunity in the guinea pig. J Invest Dermatol 1981;77:377–80. Cross Ref link Pubmed link
221 Viander M, Jansen CT, Eskola J. Influence of whole body PUVA treatments on human peripheral blood NK cell activity. Photodermatology 1984;1:23–9. Pubmed link
222 Roelandts R. Mutagenicity and carcinogenicity of methoxypsoralen plus UV‐A. Arch Dermatol 1984;120:662–9. Cross Ref link Pubmed link
223 Young AR. Photocarcinogenicity of psoralens used in PUVA treatment: present status in mouse and man. J Photochem Photobiol Biol 1990;6:237–47. Cross Ref link
224 Wang XM, McNiff JM, Klump V, et al. An unexpected spectrum of p53 mutations from squamous cell carcinomas in patients treated with PUVA. Photochem Photobiol 1997;66:294–9. Cross Ref link Pubmed link
225 Seidl H, Kreimer‐Erlacher H, Back B, et al. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A‐treated patients with psoriasis. J Invest Dermatol 2001;117:365–70. Cross Ref link Pubmed link
226 Stern RS, Bolshakov S, Nataraj AJ, Ananthaswamy HN. p53 mutation in non‐melanoma skin cancers occurring in psoralen ultraviolet A‐treated patients: evidence for heterogeneity and field cancerization. J Invest Dermatol 2002;119:522–6. Cross Ref link Pubmed link
227 Hannuksela‐Svahn A, Sigurgeirsson B, Pukkala E, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999;141:497–501. Cross Ref link Pubmed link
228 Aubin F, Donawho CK, Kripke ML. Effect of psoralen plus ultraviolet A radiation on in vivo growth of melanoma cells. Cancer Res 1991;51:5893–7. Pubmed link
229 Alcalay J, Bucana C, Kripke ML. Cutaneous pigmented melanocytic tumour in a mouse treated with psoralen plus ultraviolet A radiation. Photodermatol Photoimmunol Photomed 1990;7:28–31. Pubmed link
230 Stern RS, Khanh TN, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet radiation (PUVA). N Engl J Med 1997;336:1041–5. Cross Ref link Pubmed link
231 Stern RS and the PUVA Follow up Study. The risk of melanoma in association with long‐term exposure to PUVA. J Am Acad Dermatol 2001;44:755–61. Cross Ref link Pubmed link
232 Bruynzeel I, Bergmann W, Hartevelt HM, et al. ‘High single‐dose’ European PUVA regimen also causes an excess of non‐melanoma skin cancer. Br J Dermatol 1991;124:49–55. Cross Ref link Pubmed link
233 McKenna KE, Patterson CC, Handley J, McGinn S, Allen G. Cutaneous neoplasia following PUVA therapy for psoriasis. Br J Dermatol 1996;134:639–42. Cross Ref link Pubmed link
234 Gelfand JM, Belin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population‐based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425–9. Cross Ref link Pubmed link
235 Stern RS. Lymphoma risk in psoriasis. Results of the PUVA Follow‐up Study. Arch Dermatol 2006;142:1132–5.
236 Stern RS, Vakeva LH. Noncutaneous malignant tumors in the PUVA follow‐up study: 1975–1996. J Invest Dermatol 1997;108:897–900. Cross Ref link Pubmed link
237 Lerman S, Megaw J, Willis I. Potential ocular complications from PUVA therapy and their prevention. J Invest Dermatol 1980;74:197–9. Cross Ref link Pubmed link
238 Lerman S, Jocoy M, Borkman RF. Photosensitization of the lens by 8‐methoxypsoralen. Invest Ophthalmol Vis Sci 1977;16:1065–8. Pubmed link
239 Van Praag MCG, Tseng LNL, Mommaas AM, Boom BW, Vermeer BJ. Minimising the risks of PUVA treatment. Drug Safety 1993;8:340–9. Cross Ref link Pubmed link
240 Stern RS, Parrish JA, Fitzpatrick TB. Ocular findings in patients treated with PUVA. J Invest Dermatol 1985;85:269–73. Cross Ref link Pubmed link
241 Stern RS. Ocular lens findings in patients treated with PUVA. Photochemotherapy Follow‐up Study. J Invest Dermatol 1994;103:534–8. Cross Ref link Pubmed link
242 Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataract: a 25‐year prospective study. J Invest Dermatol 2007;57:231–7.
243 Calzavara‐Pinton PG, Carlino A, Manfredi E, et al. Ocular side effects of PUVA‐treated patients refusing eye sun protection. Acta Derm Venereol Suppl 1994;186:164–5.
244 Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. Dose‐response and time‐course characteristics of UV‐A1 erythema. Arch Dermatol 2005;141:1549–55. Cross Ref link Pubmed link
245 Mouret S, Philippe C, Gracia‐Chantegrel J, et al. UVA‐ induced cyclobutane pyrimidine dimmers in DNA: a direct photochemical mechanism? Org Biomol Chem 2010;8:1706–11. Cross Ref link Pubmed link
246 Kielbassa C, Roza L, Epe B. Wavelength dependence of oxidative DNA damage induced by UV and visible light. Carcinogenesis 1997;18:811–16. Cross Ref link Pubmed link
247 Knobler RM, Trautinger F, Graninger W, et al. Parenteral administration of 8‐methoxypsoralen in photopheresis. J Am Acad Dermatol 1993;28:580–4. Cross Ref link Pubmed link
248 Oliven A, Shechter Y. Extracorporeal photopheresis: a review. Blood Rev 2001;15:103–8. Cross Ref link Pubmed link
249 Cameron H, Dawe RS. Photosensitizing drugs may lower the narrow‐band ultraviolet B (TL‐01) minimal erythema dose. Br J Dermatol 2000;142:389–90. Cross Ref link Pubmed link
250 Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003;149:960–7. Cross Ref link Pubmed link
251 Deleu H, Roelandts R. Protecting the eye from ultraviolet A radiation during photochemotherapy. Photodermatol Photoimmunol Photomed 1990;7:233–6. Pubmed link
252 Moseley H, Jones SK. Clear ultraviolet blocking lenses for use by PUVA patients. Br J Dermatol 1990;123:775–81. Cross Ref link Pubmed link
253 Moseley H, Perkins W. Clear eyewear for PUVA patients. Br J Dermatol 1992;127:657–78. Cross Ref link Pubmed link
254 Diffey BL. Factors affecting the choice of a ceiling on the number of exposures with TL‐01 ultraviolet B phototherapy. Br J Dermatol 2003;149:428–30. Cross Ref link Pubmed link

Log in to Rooks online